Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares OutstandingShares Repurchased
Ratios

Genmab A (GNMSF) Accumulated Depreciation & Amortization (2023 - 2025)

Historic Accumulated Depreciation & Amortization for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $16.0 million.

  • Genmab A's Accumulated Depreciation & Amortization rose 4545.45% to $16.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $16.0 million, marking a year-over-year increase of 4545.45%. This contributed to the annual value of $16.0 million for FY2025, which is 4545.45% up from last year.
  • Genmab A's Accumulated Depreciation & Amortization amounted to $16.0 million in Q4 2025, which was up 4545.45% from $11.0 million recorded in Q4 2024.
  • Genmab A's Accumulated Depreciation & Amortization's 5-year high stood at $16.0 million during Q4 2025, with a 5-year trough of $8.0 million in Q4 2023.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $11.0 million (2024), whereas its average is $11.7 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 3750.0% in 2024, then skyrocketed by 4545.45% in 2025.
  • Genmab A's Accumulated Depreciation & Amortization (Quarter) stood at $8.0 million in 2023, then surged by 37.5% to $11.0 million in 2024, then surged by 45.45% to $16.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $16.0 million for Q4 2025, versus $11.0 million for Q4 2024 and $8.0 million for Q4 2023.